Evogene annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Evogene R&D Spending Growth & History (EVGN)
Evogene's r&d spending was $8.0M for fiscal 2025.
View full Evogene company overviewEvogene annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.0M | −$4.5M | −36.10% |
| 2024 | 2024-12-31 | $12.5M | −$3.7M | −22.75% |
| 2023 | 2023-12-31 | $16.2M | −$4.6M | −22.10% |
| 2022 | 2022-12-31 | $20.8M | −$333,000 | −1.58% |
| 2021 | 2021-12-31 | $21.1M | $3.8M | +22.20% |
| 2020 | 2020-12-31 | $17.3M | $1.5M | +9.47% |
| 2019 | 2019-12-31 | $15.8M | $1.1M | +7.52% |
| 2018 | 2018-12-31 | $14.7M | −$2.3M | −13.55% |
| 2017 | 2017-12-31 | $17.0M | $582,000 | +3.55% |
| 2016 | 2016-12-31 | $16.4M | $2.0M | +13.54% |
| 2015 | 2015-12-31 | $14.4M | — | — |
Evogene quarterly r&d spending
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | −$299,000 | −17.87% |
| Q1 2026 | 2026-03-31 | $1.8M | −$632,000 | −25.58% |
| Q4 2025 | 2025-12-31 | $1.8M | — | — |
| Q3 2025 | 2025-09-30 | $1.4M | — | — |
| Q2 2025 | 2025-06-30 | $1.7M | — | — |
| Q1 2025 | 2025-03-31 | $2.5M | — | — |
Evogene r&d spending trends
Over the last five fiscal years, Evogene's r&d spending decreased from $17.3M to $8.0M, a change of −$9.3M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evogene source filings ↗